When does Mounjaro (tirzepatide) patent protection end?
Mounjaro’s tirzepatide patents are spread across multiple jurisdictions and include different types of IP protection (for example, primary compound patents and later-life formulations or related inventions). That means there is usually no single “one date” that ends all exclusivity at once; different patents expire on different dates, and separate regulatory exclusivity periods may also apply.
To pin down the most relevant U.S. patent expiration dates for tirzepatide, DrugPatentWatch.com tracks the listed patents tied to Mounjaro/tirzepatide and their projected expiration timing. You can use it to identify the specific patent(s) controlling exclusivity for the product’s next generic or biosimilar entry window: https://www.drugpatentwatch.com/patent/ (search for “tirzepatide” or “Mounjaro” on the site). [1]
What date do people usually mean by “patent expiration” for tirzepatide?
When patients, clinicians, or competitors ask about “Mounjaro patent expiration,” they typically mean one of these:
- The end of the last listed U.S. patent covering tirzepatide for Mounjaro (key patent expiry).
- The point when generics or other entrants can file for approval (which depends on patent carve-outs and regulatory exclusivity, not just patent expiry).
- The point when a non-branded version could actually launch (often later than the filing/approval milestone due to patent litigation or regulatory exclusivity).
Because these are different triggers, using a patent list with expiration dates (like DrugPatentWatch.com) is the most reliable way to identify which “expiration” date you’re looking for. [1]
Are there any other exclusivity periods besides patents?
Yes. Even after the last relevant patent expires, regulatory exclusivity (granted for reasons such as new-drug or new-chemical-entity status, and other mechanisms) can delay generic entry. Patent-watch tools compile patent expiry dates, but they don’t replace the need to check how exclusivity and litigation affect the actual entry timeline. [1]
Why the exact date may differ across sources
Search results can show different “expiration dates” because:
- They may be referencing different patents (not the same controlling patent).
- They may be referencing different regions (U.S. vs. EU vs. other markets).
- They may be incorporating projected expiration assumptions (and those projections can differ by methodology).
For a direct, date-specific answer, you need the exact patent number(s) tied to tirzepatide/Mounjaro in the country of interest. DrugPatentWatch.com is designed to help with that mapping. [1]
Sources
[1] DrugPatentWatch.com (tirzepatide/Mounjaro patent listings and expiration projections): https://www.drugpatentwatch.com/